Table 1:

Clinical information of the enrolled patients

Variable	True Progression (n = 15)	Pseudoprogression (n = 22)	P Value^{^a}
Age, yr (mean ± SD)	59.6 ± 11.9	56.7 ± 13.7	.61
Gender			.12
Male	9 (60.0%)	17 (77.3%)
Female	6 (40.0%)	5 (22.7%)
Surgery			.24
Biopsy	4 (26.7%)	2 (9.1%)
Subtotal	6 (40.0%)	9 (40.9%)
Total	5 (33.3%)	11 (50.0%)
Time interval of end of TMZ-chemoradiation to DCE MRI, d (mean ± SD [range])	27.0 ± 7.3 [15–44]	28.7 ± 6.0 [17–44]	.39
End of adjuvant TMZ chemotherapy to follow-up MRI, d (mean ± SD [range])	31.2 ± 10.6 [20–53]^{^b}	26.2 ± 8.7 [16–54]	.46
Initial operation to the last follow-up, d (mean ± SD [range])	391.4 ± 156.3 [224–716]	657.3374.7 [274–1774]	.002

↵a P values are from either Student t test or the χ² test, as appropriate, for all variables.
↵b Four patients who underwent pathologic confirmation (n = 2) or developed obvious clinical deterioration before the termination of adjuvant TMZ chemotherapy (n = 2) were excluded for this parameter.